Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis

Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis

Abstract Background The BOLT study for sonidegib, a Hedgehog pathway inhibitor (HHI) approved for patients with locally advanced basal cell carcinoma (laBCC) not amenable to curative surgery or radiotherapy, used modified Response Evaluation Criteria in Solid Tumors (mRECIST) for laBCC tumor evaluat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ralf Gutzmer, Caroline Robert, Carmen Loquai, Dirk Schadendorf, Nicholas Squittieri, Ramon Arntz, Serena Martelli, Reinhard Dummer
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
Basal cell carcinoma
Hedgehog pathway inhibitor
Sonidegib
mRECIST
Tumor outcome
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/9318906b3570461fb547c379286e05d0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares